MK-8237 (SCH900237) Biomarker Study in Participants With Allergic Rhinitis or Rhinoconjunctivitis (MK-8237-009)

Inclusion Criteria: Part 1: * healthy participants * has a Body Mass Index (BMI) =\< 30 kg/m\^2 * female of reproductive potential remains abstinent or uses two acceptable methods of birth control from 2 weeks before first allergen challenge to 2 weeks after last allergen challenge; alternatively hormonal contraception may be used. Part 2: * has a Body Mass Index (BMI) =\< 38 kg/m\^2 * has a clinical history of allergic rhinitis/rhinoconjunctivitis to HDM for at least one year, and used medication to relieve symptoms within the last year * does not have asthma, or has mild controlled asthma not requiring regular use over the 12 months prior to screening of any corticosteroids * female of reproductive potential remains abstinent or use two acceptable methods of birth control from 2 weeks before first allergen challenge to at least 2 weeks after last allergen challenge or last dose of study drug, whichever is longer * has not smoked or used tobacco for the prior 6 months, and agrees not to during study Exclusion Criteria: Parts 1 and 2: * is experiencing at the first NAC visit, symptoms from an upper or lower respiratory tract infection (viral or bacterial) * has participated within the prior 3 months in another investigational study (that included an investigational drug or agent) * is directly associated with the administration of the study or is related to the investigational study staff * is mentally or legally incapacitated, has significant emotional problems or has a history of clinically significant psychiatric disorder within the past 5 years * has a history of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary or major neurological (including stroke and chronic seizures) abnormalities or diseases * has a history of cancer * has a history of significant intolerability to drugs or food * is positive for hepatitis B surface antigen, hepatitis C antibodies or HIV * had major surgery or lost 1 unit (500 mL) of blood within the prior 4 weeks * has a clinical history of chronic sinusitis during the prior 2 years * has any nasal condition (e.g. nasal polyposis) that could confound efficacy or safety assessments * is pregnant or expects to conceive during the study period * is a nursing mother * consumes more than 3 glasses of alcoholic beverages per day * regularly uses any illicit drug, or has a history of drug or alcohol abuse within the prior 6 months Part 2 only: * is experiencing allergic rhinoconjunctivitis exacerbation at Screening NAC * consumes excessive daily amounts of caffeinated beverages * has a known history of allergy, hypersensitivity or intolerance to investigational medicines * is sensitized and regularly exposed to animal dander and molds in the home or workplace in a manner that might interfere with the study in the opinion of the investigator * is sensitized and regularly exposed to seasonal allergens such as Birch or grass pollen (sensitized but out of season is acceptable however) * has a history of chronic urticaria and/or angioedema within the prior 2 years * has had previous immunotherapeutic treatment with any HDM allergen for more than 1 month during the prior 3 years * is receiving any specific immunotherapy within prior 60 days * has a history of anaphylaxis with cardiorespiratory symptoms with prior immunotherapy due to an unknown cause or an inhalant allergen